Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder (Q33945438)

30 July 2017

1 reference

title

Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder (English)

1 reference

adult attention deficit hyperactivity disorder

30 July 2017

main subject

0 references

author name string

Horrigan JP

series ordinal

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Expert Opinion on Pharmacotherapy

30 July 2017

published in

1 reference

30 July 2017

volume

2

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

573-586

1 reference

Treatment of attention-deficit-hyperactivity disorder

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Problems in the management of attention-deficit-hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

21 January 2018

Dopamine genes and ADHD.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Dopamine transporter density in patients with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

21 January 2018

Stimulant medications

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Pemoline for the treatment of cocaine dependence in methadone-maintained patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Selegiline in ADHD adults: plasma monoamines and monoamine metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Donepezil therapy in clinical practice: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Donepezil for Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Pharmacotherapy of Adult Attention Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

Attention-Deficit/Hyperactivity Disorder and Substance Use: Symptom Pattern and Drug Choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.573

21 January 2018

Identifiers

DOI

10.1517/14656566.2.4.573

1 reference

30 July 2017

1 reference